Patents Assigned to CALDERA HEALTH LIMITED
-
Patent number: 8784795Abstract: The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.Type: GrantFiled: July 3, 2013Date of Patent: July 22, 2014Assignee: Caldera Health LimitedInventors: James D. Watson, Richard Llewellyn Sydney Forster
-
Publication number: 20140135232Abstract: Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject.Type: ApplicationFiled: December 18, 2013Publication date: May 15, 2014Applicant: CALDERA HEALTH LIMITEDInventors: James Douglas WATSON, Richard Llewellyn Sydney FORSTER, Damian Jay WHITE
-
Patent number: 8703127Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.Type: GrantFiled: January 13, 2012Date of Patent: April 22, 2014Assignee: Caldera Health LimitedInventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
-
Patent number: 8658166Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.Type: GrantFiled: September 19, 2012Date of Patent: February 25, 2014Assignee: Caldera Health LimitedInventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
-
Patent number: 8658164Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.Type: GrantFiled: June 29, 2012Date of Patent: February 25, 2014Assignee: Caldera Health LimitedInventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
-
Patent number: 8632971Abstract: Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject.Type: GrantFiled: August 30, 2012Date of Patent: January 21, 2014Assignee: Caldera Health LimitedInventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
-
Publication number: 20130116133Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.Type: ApplicationFiled: January 13, 2012Publication date: May 9, 2013Applicant: CALDERA HEALTH LIMITEDInventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
-
Publication number: 20130116140Abstract: Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject.Type: ApplicationFiled: August 30, 2012Publication date: May 9, 2013Applicant: CALDERA HEALTH LIMITEDInventors: James Douglas WATSON, Richard Llewellyn Sydney FORSTER, Damian Jay WHITE
-
Publication number: 20130115604Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.Type: ApplicationFiled: June 29, 2012Publication date: May 9, 2013Applicant: CALDERA HEALTH LIMITEDInventors: James Douglas WATSON, Richard Llewellyn Sydney FORSTER, Damian Jay WHITE
-
Publication number: 20130116131Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.Type: ApplicationFiled: November 8, 2011Publication date: May 9, 2013Applicant: CALDERA HEALTH LIMITEDInventors: James Douglas WATSON, Richard Llewellyn Sydney FORSTER, Damian Jay WHITE
-
Publication number: 20130116142Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.Type: ApplicationFiled: September 19, 2012Publication date: May 9, 2013Applicant: CALDERA HEALTH LIMITEDInventor: Caldera Health Limited